The FLASH study was designed to assess treatment with polylactic acid for facial fat loss - a condition called lipoatrophy associated with taking HIV drugs
Polylactic acid (marketed as Sculptra and also formerly known as New-Fill) is a substance which is injected into areas of the face affected by fat wasting. Participants in the trial were randomly assigned to receive the treatment immediately or after a six-month delay
This study will compare people who are hypersensitive to three particular drugs with people who are not. The three drugs - nevirapine, efavirenz and abacavir - are all known to cause hypersensitivity reactions in a small number of people and so the study is looking for particular immune system markers which might predict who can safely take them and who might have reactions to them.
This is an observational study. There is no experimental treatment associated with this trial.
This is an observational study looking at a particular genetic sequence sometimes found in the immune system which is directly associated with the risk of developing a hypersensitivity reaction (a severe, sometimes life-threatening reaction) to the HIV antiretroviral drug abacavir. The genetic sequence associated with this problem is known as HLA-*B5701 and it is present in a small percentage of the population. It is this percentage of people who are at risk of a severe reaction when they start abacavir, so it is not used in people who have this genetic trait.
This trial will evaluate whether an experimental drug (NGX-4010) is both safe to use and an effective treatment for the pain resulting from HIV-associated neuropathy.
The study drug contains capsaicin - a substance found in chilli peppers - and is applied to the skin as a patch.
This is a randomised study where people receive either a low concentration patch (acting as placebo) or a high concentration patch for a period of 30 or 60 minutes.
This study is looking for people who take or have taken nevirapine as part of their drug regimen. The study wants to see if there are any genetic differences which may help predict who is likely to react badly to the drug.
This is an observational study, looking at the effect HIV treatment has on the health of our heart. The investigators are comparing how well cholesterol is processed by those not on therapy with those who are on treatment. They are also comparing those on NNRTI-based regimens with those on PI- based ones.
This study is observing the way different treatment strategies affect nerve and brain function.
This information was retrieved from the Treataware website (www.treataware.info) on 5 Dec 2008. For further information, please consult the website or call the NAPWA office on 02 8568 0300.